Navigation Links
Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
Date:5/5/2011

of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.


'/>"/>
SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... 12, 2011 Unilife Corporation ("Unilife" or the "Company") ... the development of its AutoInfusor™ portfolio of subcutaneous infusion ... 5mL, 7mL, and 10mL volumes. Unilife has ... of pharmaceutical and biotechnology companies with drugs that have ...
... one of the largest distributors of high-performance and engineering-grade ... new EVONIK VESTAKEEP® 5000 PEEK extruded stock shapes. ... most ductility of any PEEK material available in extruded ... Marketing at Modern Plastics. EVONIK VESTAKEEP® ...
Cached Medicine Technology:Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 2Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 3Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 4
(Date:5/18/2013)... PA (PRWEB) May 18, 2013 Simple ... indulging in healthy snacks and drinking more water can ... loss and, ultimately, a healthier lifestyle overall. Diet ... achieve the best weight loss can be difficult and ... into their diet plans to help patients get over ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
(Date:5/18/2013)... Francisco, CA (PRWEB) May 18, 2013 ... appointments for 2013 therapies. At the Ayurvedic Spa ... guidance of panchakarma practitioner and lifestyle recommendations ... Ayurveda, the “knowledge of life", is the traditional healthcare ... that a life of harmony is the basis for ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
(Date:5/18/2013)... Scott Tischler of Tischler Brothers Fitness helped Troy Tischler ... losing weight played a huge part in Troy Tischler's weight ... was able to lose a pound a day. It is ... approached with caution and any activity should be stopped if ... weight loss that Scott Tischler advocates. With these five keys ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Network, the prominent advocacy group launches the inaugural World ... site, www.worldmrsaday.org . MRSA activists ... and the community for a greater response to the ... alarming rate.MRSA Survivors Network, the official organization for World ...
... 5 The World Health Organization says a Swine ... already declared emergencies. Many experts believe the Federal government ... the outbreak takes on the public will become increasing ... of panic. Your only defense: to prepare your department ...
... Give Voice to Improving Quality Care and Quality Careers , ... for better senior living, celebrates National Nurse Week May 6-12, ... how to improve the business, the quality of care and ... Vigilan is offering an online and phone-based survey where ...
... Indiana University School of Medicine , the not-for-profit Taking Control ... for people living with diabetes on May 30 from 9 ... The TCOYD conference, lunch and health fair brings national and ... types of diabetes, those at risk for diabetes, and their ...
... Society of Cellular Therapy (ISCT) Demonstrating Potential to ... in TransplantationOLDSMAR, Fla., May 5 /PRNewswire-FirstCall/ -- ... new study showing that adding menstrual blood stem ... blood expands the number of progenitor cells (cells ...
... Inc. (Nasdaq: CYNO ), a ... light-based aesthetic treatment systems, today announced financial results for ... 2009 Financial Results , Consistent with Cynosure,s ... March 31, 2009 were $14.8 million, reflecting the continued ...
Cached Medicine News:Health News:MRSA Activists Rally For World MRSA Day 2Health News:Ready or Not - Flu Pandemic Has Arrived 2Health News:Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care 2Health News:Taking Control of Your Diabetes Conference Returns to Indianapolis to Bring Answers, Advocacy and Hope for People With Diabetes 2Health News:Taking Control of Your Diabetes Conference Returns to Indianapolis to Bring Answers, Advocacy and Hope for People With Diabetes 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 2Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 4Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 5Health News:Cynosure Reports Financial Results for the First Quarter of 2009 2Health News:Cynosure Reports Financial Results for the First Quarter of 2009 3Health News:Cynosure Reports Financial Results for the First Quarter of 2009 4Health News:Cynosure Reports Financial Results for the First Quarter of 2009 5Health News:Cynosure Reports Financial Results for the First Quarter of 2009 6Health News:Cynosure Reports Financial Results for the First Quarter of 2009 7Health News:Cynosure Reports Financial Results for the First Quarter of 2009 8Health News:Cynosure Reports Financial Results for the First Quarter of 2009 9Health News:Cynosure Reports Financial Results for the First Quarter of 2009 10
Prolactin EIA Reproductive Markers 025-BC-1037...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
... (pregn-4-ene-3, 20-dione) is a C21 steroid hormone ... bond between C-4 and C-5 (?4).,This steroid ... in conjunction with estrogens, regulates,the accessory organs ... particularly important in preparing the,endometrium for the ...
... also known as Kininase II, is a ... weight of at least 129,000. The structure ... chain, a polysaccharide residue and a zinc ... cell types such as neuronal cells and ...
Medicine Products: